pipeline

Biopharmaceutical Candidates

좌우스크롤 이미지After clicking on the screen, please scroll down at the bottom or move the screen left or right.

Candidate Active Substance Therapeutic Area Discovery Process Dev. Preclinical Phase I Phase II Phase III Approval
RBB-002 Biobetter Engineered Aflibercept nAMD etc.

 
RBA-004 Bispecific Ab Cancer Inflammation.

 
RBG-005 Gene therapy Sjögren's Syndrome

 
Molecular Substance
Fusion Protein
Mechanisms
VEGF & PIGF Inhibitors
Benefits
Increasing the size of the biopharmaceutical protein will also increase the half-life of the drug in the body. Modifying the Fc receptor to have an enhanced binding affinity will also prolong the duration of the drug in the body.

Age-Related Macular Degeneration

The main cause of degenerative changes of the macula are due to aging, and they occur in about 10% of the population aged 55~74 and about 30% of the population aged 75~84.
Macular degeneration is one of the most common causes of blindness in adults over the age of 55 in major developed countries in the world, so early diagnosis and treatment are of utmost importance.
Molecular Substance
Recombinant antibody therapy
Mechanisms
As part of the method of normalizing cytokine imbalance, which causes autoimmune diseases, the action of the transcription factor STAT3 is inhibited to prevent the overexpression of TNF-α and IL-6, which are known to play an important role in the inflammatory response, to achieve the therapeutic effect.
Note
Developed as a cell-penetrating bi-specific antibody to inhibit the action of STAT3, which acts as a transcription factor inside cells. In particular, considering the mechanism of action of STAT3, which is activated through phosphorylation of tyrosine residue, we developed an antibody that can selectively inhibit only STAT3 with phosphorylation.
Benefits

By selectively inhibiting only activated STAT3 using cell penetration bi-specific antibodies, it is possible to achieve a therapeutic effect that controls the autoimmune inflammatory response while minimizing unnecessary side effects or toxicity.

Ripple effect
The successful development of cell penetrating bi-specific antibodies can lead to the development of targeted therapies that inhibit the action of many types of transcription factors that play an important role in cells, which has the potential to lead to the effective development of cardiovascular disease therapeutics and anticancer target therapies as well as more than 100 autoimmune diseases.
Treatment type
siRNA gene THERAPY USING ADENO-ASSOCIATE VIRUS (AAV-2)
Mechanisms
Using siRNA to inhibit BMP-6 overexpression in patients with Sjögren's syndrome
Note
A. Synthetic gene promoter technology
B. Personalized medicine according to the patient's genetic profile
Benefits
Inhibition of the expression of BMP-6 through siRNA leads to an increase in the expression of Aquaporin-5, a water channel protein, in salivary gland cells, thereby promoting normal secretion of the salivary glands, relieving symptoms and preventing lesion enlargement

Sjögren's syndrome

It is a type of autoimmune disease and is a chronic disease that causes a systemic inflammatory response, including symptoms such as dry mouth and dry eyes, which significantly worsens the patient's quality of life, and there is currently no appropriate causative treatment for Sjögren's syndrome.

The therapeutic goal of Rophibio is to inhibit the overexpression of BMP6, which is observed in about 60% of patients with Sjögren's syndrome, and to reduce it to the level of normal people, and as a salvage, it applies a method of inhibiting the expression of BMP6 by injecting an adeno-associate virus (AAV) vector equipped with BMP6 RNAi directly into the patient's salivary glands.

In particular, in order to increase the safety of gene therapy products, we use Rophibio's patented artificial gene promoter technology to develop targeted therapies in which the effect of gene therapy administered is limited to target cells by applying a targeting promoter that works only on the patient's salivary gland cells.

Furthermore, we are developing patient-specific treatments by using the genetic profiles of patients with Sjögren's syndrome to derive the patient group that can achieve the most efficient therapeutic effect of BMP6 RNAi.